跳至主要内容
临床试验/NCT00264459
NCT00264459已完成3 期

A Multicentre, Placebo-controlled, Double-blind Study to Evaluate Efficacy and Safety of a Perennial Sublingual Specific Immunotherapy With a Liquid Formulation of an Extract of a Six Grass Pollen-mixture in Patients With Clinically Relevant Grass Pollen Sensitivity.

Allergopharma GmbH & Co. KG1 个研究点 分布在 1 个国家目标入组 160 人开始时间: 2003年2月1日最近更新:
适应症
干预措施

试验速览

阶段
3 期
状态
已完成
入组人数
160
试验地点
1
主要终点
Symptom and Medication Score (SMS)

研究概览

简要总结

The trial is performed to asses efficacy and safety of a sublingual extract of a six grass pollen mixture

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Rhinitis, Rhinoconjunctivitis, Positive Rast result to grass pollen, Positive skin prick test to grass pollen, Positive specific provocation to grass pollen,

排除标准

  • •Serious chronic diseases, Other perennial allergies

研究组 & 干预措施

Placebo

Placebo Comparator

Placebo was given the same way as a sublingual preparation.

干预措施: Comparator (Other)

Liquid formulation of an extract of a 6 grass pollen mixture

Experimental

Sublingual application containing allergen extracts of 6 grass pollen species (Holcus lanatus, Dactylus glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca pratensis) pollen allergen extract.

The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter. Initial treatment was applied on the first day of treatment with a starting dose of 25% of the maintenance dose. Increasing doses of 50% were applied with the second and 100% with the third dose to give the maximum (=maintenance) dose. This was followed by a daily patient selfadministered treatment with the maintenance dose.

干预措施: Grass pollen formulation (Biological)

结局指标

主要结局

Symptom and Medication Score (SMS)

时间窗: 1.5 years of therapy

The primary endpoint is the change of the area under the curve (AUC, derived from an analysis period of 42 days) of the daily sum of the Symptom and Medication Score (SMS) from the baseline measurement to the measurement after 1.5 years of therapy.

次要结局

  • Visual Rating Scale(1.5 years)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验